+++ Nach d.GPC-Hype könnten spekulativ-orientierte Anleger bei diesem - 500 Beiträge pro Seite

[icepak]

Wert einsteigen:

STARPHARMA POOLRD LTD. WKN: 796 461

Streng limitieren !

[icepak]

Seit ein paar tagen bei uns handelbar!

Könnte was werden, ich finde es interessant!


Comment von; siehe unten


Besonders reizvoll:

Doppelte Phantasie durch Symbiose von Biotech und Nanotech und dann noch Firstmovervorteil und milliardenschwerer AIDS-Markt!!!

Seit kurzem handelbar und heute schon sehr gut gelaufen. Hier eine Artikel aus dem " Aktienboard" :

Starpharma hat gute Chancen auf den ersten Nanowirkstoff

Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat.

Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.

Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll nun auf seine Wirksamkeit gegen HIV getestet werden.

Ebenfalls im Juli erst erhielt Starpharma für sein auf Nanopartikeln basierendes Gel zur HIV-Prävention die FDA-Genehmigung zur Durchführung eines Phase I Versuches. Damit ist das von Starpharma entwickelte VivaGel das erste!!! auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.

Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen blockieren und dadurch eine Infektion verhindern. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.

Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Mit speziellen chemischen Prozessen wird eine präzise Kontrolle der physikalischen und chemischen Eigenschaften der Dendrimere möglich. Die Dendrimere werden in einer Serie von kontrollierten Reaktionsschritten konstruiert, dabei ordnen sich viele kleine Moleküle um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.

In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle.

Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprachen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.

Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit mechanischen Barrieren eindämmen.

Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein wohl bisher kaum abschätzbares Marktvolumen erwarten.

Eine Studien zum Thema BioNanotechnologie, einschließlich der Vorstellung von interessanten Unternehmen, finden Sie auch auf unserer Webseite unter www.Biotech-Experte.de.

Als Abonnent unseres Service erhalten sie alle einmal monatlich erscheinenden Studien sogar ohne zusätzliche Kosten.

Das Team von Biotech-Experte.de besitzt die erforderliche wissenschaftliche Expertise, die für ein erfolgreiches Investment im LifeScience Sektor unabdingbar ist. Wenn auch Sie von unserem Wissen profitieren wollen, zögern Sie nicht länger, sondern kontaktieren Sie uns noch heute. Unter www.Biotech-Experte.de erfahren Sie näheres zu unserem Service sowie zu unseren Expertisen.

Simone A. Hörrlein
Staatl. gepr. LebChem (Univ.)
(Life Scientist)






·

[icepak]

WKN/Ticker 796.461/PQ6

STARPHARMA POOLED DEVELO

[PlanschProtectionTeam]

[icepak]

Anfang letzten Jahres hatte ich folgende Werte alle um 1 Euro auf der WL

Nonogene
Nanophase
Nanometrices

ein Blick auf den Kursverlauf sollte sich lohnen !



Nur mal so!


Company Overview
Starpharma Pooled Development Ltd is an ASX listed company established in 1996 to develop a polyvalent technology based on large molecules called dendrimers. Commencing in 1992, the Biomolecular Research Institute (BRI) in Melbourne, Australia, first investigated dendrimers as protein mimics for pharmaceutical applications, before licensing the technology to Starpharma Pooled Development Ltd’s subsidiary company, Starpharma Pty Ltd (“Starpharma”.

Today, Starpharma Pooled Development Ltd has parallel investments to develop both pharmaceutical and non-pharmaceutical applications of dendrimer nanotechnology.

Dendrimer nanotechnology...
Dendrimers are synthetic, nanoscale compounds with unique features and benefits making them useful for development as pharmaceuticals, and for incorporation in new and existing products. Starpharma creates dendrimers to achieve polyvalent (i.e. multiple) interaction with biological targets across a wide range of diseases. Dendrimers can be designed to achieve novel pharmaceutical properties. Our dendrimer technologies are also enabling technologies that offer defined nanostructures capable of being developed and modified to offer solutions for problems in a broad range of industries, including medical (e.g. pharmaceutical), material, chemical and electronic.

Creating value...
The company aims to create value for investors from dendrimer nanotechnology by growing and utilising our team’s core skills in dendrimer and medicinal chemistry, and associated development, commercialisation and regulatory compliance activities to:

advance selected pharmaceutical products through early stage development;
extend our IP position through partnerships and licensing;
partner with pharmaceutical and other companies to provide new opportunities and solve problems.
Starpharma Pooled Development Ltd is a registered pooled development fund (PDF) with investee companies under the Starpharma Group. Starpharma Proprietary Limited manages the group’s activities associated with the development and commercialisation of dendrimers for pharmaceutical applications. Dendritic Nanotechnologies, Inc. (DNT) carries out the development and commercialisation of dendrimers for non-pharmaceutical applications.

Development Opportunities ...
Starpharma’s current development programs focus on compounds with therapeutic activity in the following specific disease areas:

Sexually Transmitted Diseases (e.g. HIV)
Respiratory Viruses (e.g. influenza, RSV)
Systemic Viral Diseases (e.g. HBV)
Cancer (angiogenesis)
Biodefense and Tropical Diseases (toxins, exotic viruses)
The company has a very active program to explore the potential of dendrimers in a wide range of other diseases.

Product Opportunities ...
Starpharma is seeking strategic alliances and license arrangements with pharmaceutical companies for the development of its dendrimers that have demonstrated activity against a wide range of diseases.

Platform Opportunities ...
Starpharma also is keen to work with companies to enable the incorporation of this platform technology into new and existing pharmaceutical products.


Corporate Structure
Starpharma Pooled Development Ltd’s structure reflects the activities it focuses on as it develops its intellectual property and licensing opportunities. As a registered pooled development fund, shareholders are entitled to significant taxation benefits. Starpharma Pooled Development Ltd currently invests in the following companies:

Starpharma Pty Ltd is a wholly-owned subsidiary and holds the IP rights for pharmaceutical applications of the technology. Starpharma Pty Ltd manages the group’s activities associated with the development and commercialisation of dendrimers for pharmaceutical applications.
Viralstar Pty Ltd is a wholly-owned subsidiary and has agreed to provide research funding for further development of the technology in the field of antiviral therapeutics. Viralstar Pty Ltd may become involved in the commercialisation process of this area of the technology.
Angiostar Pty Ltd is a wholly-owned subsidiary and has agreed to provide research funding for further development of the technology in the field of inhibition of angiogenesis. Angiostar Pty Ltd may become involved in the commercialisation process of this area of the technology.
Dendritic Nanotechnologies, Inc. (“DNT” is a US incorporated company based in Michigan, USA. Starpharma Pooled Development Ltd is the largest shareholder in DNT. DNT has IP rights to a large body of dendrimer and dendritic polymer related IP, and is dedicated to further research, production and commercialisation of this IP. DNT and Starpharma collaborate on the development and commercialisation of dendrimer technology IP. For further information see: www.dnanotech.com.

Dendrimer Nanotechnologies, Inc. (DNT)
“The Dendrimer Store...”
DNT is a US Delaware incorporated company with research and development operations located at the Center for Applied Research and Technology (CART) at Central Michigan University in Mount Pleasant, Michigan, USA. DNT was established as an Australian company by Starpharma Pooled Development Ltd as a joint venture with the pioneer of dendrimer nanotechnology, Donald A. Tomalia, PhD. In October 2002, the Australian PDF Registration Board gave permission for Starpharma Pooled Development to remain the largest shareholder of DNT after its conversion to a US incorporated company, allowing shareholders of Starpharma Pooled Development Ltd to retain PDF taxation benefits, while maximising international opportunities for DNT. Starpharma Pooled Development Ltd is the largest shareholder of DNT.

Starpharma invested in the creation of DNT to create value for shareholders of Starpharma Pooled Development Ltd by advancing the development and commercialisation of complementary applications of dendrimer nanotechnology. Starpharma Pooled Development Ltd has completed its capital investment in DNT, which is now financially independent.

DNT’s objectives are to create value from dendrimer and dendritic polymer technology by:

creating novel dendritic intellectual property through innovative design and synthesis;
being the leading supplier of high quality, innovative new dendrimers;
establishing commercialisation partnerships, joint ventures and spinning out new companies in the areas of energy storage, drug delivery and light generation.
Important achievements and events for DNT include:

On completion of the establishment of DNT in July 2002, Dr Tomalia granted intellectual property licenses to DNT for his rights to 33 patent families, involving 182 granted patents worldwide, related to dendrimers and dendritic polymers (News);
DNT is a beneficiary of a US biodefense grant worth US$3.5 million for one year, which will help establish DNT and Central Michigan University as a Center for Dendrimer Nanotechnology (News);
Charles Burke, PhD, was appointed the company’s founding Chief Executive Officer in November 2002. Dr Burke was previously CEO of Research Biochemicals International, a chemical synthesis and development company now owned by Sigma-Aldrich (Sigma-RBI) (News);
DNT was converted to a US incorporated entity in March 2003;
DNT’s dendrimer chemists are expanding the company’s intellectual property portfolio and continue to establish novel dendritic scaffolds and other materials;
DNT is generating revenue through the sale of high value, high quality and reproducible research-grade dendrimer products through Aldrich Chemical Company;
DNT was selected as an industrial partner of Massachusetts Institute of Technology’s (MIT) Institute for Soldier Nanotechnologies (News);
DNT appointed to its team a Director of the Board and a part-time CFO, former employees of Dow Corning, and a senior scientist, a former employees of Dow Chemical (News);
DNT is currently negotiating licensing and collaborative research agreements with companies involved in a diverse range of industries, including electronics.
DNT plans to enter commercial and scientific collaborations and develop partnerships with third parties to commercialise dendrimer nanotechnologies in all areas of application. Starpharma Pty Ltd has exclusive development and commercialisation rights to existing and new intellectual property in DNT for applications in the pharmaceutical sector. This arrangement expands and strengthens Starpharma’s position in dendrimer-based pharmaceuticals.

The potential for dendrimer technology to be incorporated into new or existing products in pharmaceutical and other areas is significant. Already, companies worldwide are incorporating dendrimers in clinical diagnostic assays, ink toners, paints, chemical catalysts and other products.

Visit DNT’s Dendrimer Store at www.dnanotech.com.

About PDFs
A Pooled Development Fund (PDF) is an Australian company that is registered and regulated by the PDF Board in accordance with the Pooled Development Funds Act 1992 (Cth). The objective of the PDF Act is to encourage the provision of patient equity capital for growing small to medium sized enterprises by conferring certain tax benefits to investors in a PDF. Starpharma was registered as a PDF on 23 July 1997.

Taxation Benefits...
Shareholders in a PDF who realise a capital gain on their investment or receive a dividend will, in general, not be taxed on either the capital gain or dividend income.

Important:
Potential investors should obtain their own professional taxation advice or make their own inquiries if the taxation treatment of PDFs is material to their investment.

Corporate Governance
Starpharma Pooled Development Limited (the Company) and the Board are committed to achieving and demonstrating the highest standards of corporate governance. This Corporate Governance Statement reflects the corporate governance practices that have been in place throughout the financial year ended 30 June 2003. On 31 March 2003 the ASX Corporate Governance Council released its "Principles of Good Corporate Governance and Best Practice Recommendations". Whilst the Company`s current practices substantially accord with these principles and recommendations, the Company has undertaken a process to review its corporate governance practices and will make a full statement on its compliance with the best practice recommendations in its 2004 Annual Report.


A description of the Company‘s main corporate governance practices is set out below. All these practices, unless otherwise stated, were in place for the financial year 2002/2003.


The Board of Directors and its Committees
The Board is responsible for the overall corporate governance of the Company and its controlled entities, including development of corporate strategies, establishing goals for management and monitoring progress towards the achievement of these goals.

Composition of the Board
The Constitution of the Company requires that one third of directors (or if their number is not a multiple of three then the number nearest to one third) retire at every annual general meeting and be eligible for re-election. The minimum number of directors is three and the maximum is fifteen unless the Company passes a resolution varying that number.

The Chairman is an independent non-executive director who is elected by the full Board and meets regularly with the Chief Executive Officer.


The Board currently consists of five non-executive directors and one executive director, Dr J W Raff. Details of the members of the Board, their experience, qualifications and term of office are set out on this website and in the Directors` Report under the heading "Information on Directors" in the 2003 Annual Report.


Responsibilities of the Board
The responsibilities of the Board include:


Contributing to the development of and approving the corporate strategy;
Reviewing and approving business plans, the annual budget and financial plans including available resources and major capital expenditure initiatives;
Overseeing and monitoring organisational performance and the achievement of the Group`s strategic goals and objectives;
Monitoring financial performance including approval of the annual and half-year financial reports and liaison with the Company`s auditors;
Ensuring there are effective management processes in place and approving major corporate initiatives;
Enhancing and protecting the reputation of the Company;
Ensuring the significant risks facing the Company, including those associated with its legal compliance obligations have been identified and appropriate and adequate control, monitoring, accountability and reporting mechanisms are in place;
Reporting to shareholders.

Commitment
Board meetings are held on a monthly basis, or more frequently if required. The number of meetings of the Board and of each Board committee held during the year ended 30 June 2003 and the number of meetings attended by each director is disclosed in the Directors` Report in the 2003 Annual Report. The commitments of non-executive directors are considered by the Remuneration and Nomination Committee prior to the directors` appointments to the Board and are reviewed each year as part of an annual performance assessment.

Prior to appointment or being submitted for re-election each non-executive director is required to specifically acknowledge that they have and will continue to have the time available to discharge their responsibilities to the Company.


Chairman and Chief Executive Officer

The Chairman is responsible for leading the Board, ensuring that the Board activities are organised and efficiently conducted and ensuring directors are properly briefed for meetings. The Chief Executive Officer is responsible for implementing Company strategies and policies. The Board policy is for these separate roles to be undertaken by separate people.


Administrative Structure and Internal Control Framework
Detailed management reports are prepared by senior management and distributed with Board papers prior to each meeting. The Chief Executive Officer and the Company Secretary attend all Board meetings. Other senior executives may be asked to attend Board meetings to report on or discuss specific agenda items.


Conflict of Interests

Entities associated with Prof Peter Colman, Mr Ross Dobinson and Mr Leon Gorr had business dealings with the consolidated entity during the year, as described in note 25 to the financial statements contained in the 2003 Annual Report. The directors concerned declared their interests in those dealings to the Company and took no part in decisions relating to them or the preceding discussions. In addition, those directors did not receive any Board papers relating to those dealings.


Independent Professional Advice
Directors have the right, in connection with their duties and responsibilities, to seek independent professional advice at the Company‘s expense. Prior approval of the Chairman is required, but this approval will not be unreasonably withheld.

Corporate Reporting

The Chief Executive Officer and the Company Secretary have made the following certifications to the Board:


that the Company`s financial reports are complete and present a true and fair view, in all material respects, of the financial condition and operational results of the Company and consolidated entity;

that the above statement is founded on a sound system of internal control and risk management which implements the policies adopted by the Board and that the Company`s risk management and internal control is operating efficiently and effectively in all material respects.
The Company adopted this reporting structure for the year ended 30 June 2003.

Ethical Standards
The directors are committed to the principles underpinning best practice in corporate governance, with a commitment to the highest standards of legislative compliance and financial and ethical behaviour.

Trading in Company Securities
The purchase and sale of Company securities by directors, executives and employees is only permitted during the thirty day period following the annual general meeting and the release of the half-yearly and annual financial results to the market, unless prior approval is given to each transaction by the Chairman.

Board Committees
The Board has established a number of Committees to assist in the execution of its duties and to allow detailed consideration of complex issues. The committee structure and membership is reviewed on an annual basis. All matters determined by committees are submitted to the full Board as recommendations for Board decisions. Current committees of the Board are the following:


Audit Committee
The Audit Committee consists of Mr Ross Dobinson (Chairman) and Mr Leon Gorr. The Committee meets at least twice a year, and has direct access to the Company‘s auditors. The charter of the Audit Committee is:

to review and report to the Board on the annual report and financial statements, and to review the adequacy of external audit arrangements, particularly the scope and quality of the audit;
to provide assurance to the Board that it is receiving adequate, up to date and reliable information;
to assist the Board in reviewing the effectiveness of the organisation`s internal control environment covering:
effectiveness and efficiency of operations
reliability of financial reporting
compliance with applicable laws and regulations;
to assist the Board in the development and monitoring of risk management, statutory compliance and ethics programs.
Subsequent to the end of the financial year, Dr Peter Jenkins joined the Audit Committee as an additional member.


Remuneration and Nomination Committee
The Remuneration and Nomination Committee consists of:

Mr Peter T. Bartels (Chairman)
Mr Ross Dobinson
The main responsibilities of the Committee are to:


propose candidates for Board vacancies;
oversee Board succession including the succession of the Chairman;
conduct annual reviews of Board membership having regard to present and future needs of the Company and make recommendations on Board composition and appointments;
advise the Board on remuneration policies and practices generally;
make specific recommendations on remuneration packages and other terms of employment for executive directors, other senior executives and non-executive directors.

When the need for a new director is identified or an existing director is required to stand for re-election, the Committee reviews the range of skills, experience and expertise on the Board, identifies its needs and prepares a short-list of candidates with appropriate skills and experience. Where necessary, advice is sought from independent search consultants.

Each member of the senior executive team has signed a formal employment contract covering a range of matters including their duties, rights, responsibilities, and any entitlements on termination. The standard contract refers to a specific formal position description.

Research Committee
This is a Committee of the Board of the controlled entity Starpharma Pty Ltd and consists of Dr Peter Jenkins (Chairman), Prof Peter Colman and Dr John Raff. The charter of the Research Committee is:

to ensure that the Boards of Starpharma Pooled Development Limited and its controlled entities are kept fully informed of developments relating to the Company‘s research activities and development progress against milestones; and
to advise the Board of Starpharma Pooled Development Limited on scientific matters in relation to the Company‘s continuous disclosure obligations under the Listing Rules of the Australian Stock Exchange.
The Environment, Occupational Health and Safety
The Board recognises the importance of environmental and occupational health and safety issues and is committed to the highest levels of performance. The Company has adopted an Occupational Health and Safety (OH&S) Policy and established an OH&S Committee as part of its overall approach to workplace safety. This Committee meets regularly to ensure the development and implementation of OH&S policy and procedures, and to ensure compliance with relevant legislation and guidelines.

The Chief Executive Officer is represented on the OH&S Committee by the Company Secretary.

Continuous Disclosure
The Company Secretary has been appointed as the person responsible for communications with the Australian Stock Exchange Limited (ASX). This person is also responsible for ensuring compliance with the continuous disclosure requirements in the ASX Listing Rules and overseeing and co-ordinating information disclosure to the ASX, analysts, brokers, shareholders, the media and the public.


Dendrimer Nanotechnology
Small science...
Nanotechnology is the manipulation of matter, molecule by molecule, to create new materials with novel, tailored properties. Dendrimers (dendri - tree, mer - branch) are synthetic, nanoscale structures that can be tailored for various applications. Specialised chemistry techniques allow for precise control over the physical and chemical properties of the dendrimers. They are constructed generation by generation in a series of controlled steps that increase the number of small branching molecules around a central core molecule. The final generation of molecules added to the growing structure makes up the polyvalent surface of the dendrimer. The core, branching and surface molecules are chosen to give desired properties and functions.



Dendrimers allow man for the first time to produce highly defined and biocompatible nanoscale objects built from the bottom up. This high definition enables unique functionality of dendrimers in life science applications and industries including medical, electronics, chemicals and materials.

Innovative, polyvalent pharmaceuticals...
Dendrimers may be designed and synthesised to achieve a polyvalent interaction, meaning that a single dendrimer can have multiple, simultaneous attachments to biological targets (e.g. cell surface).

Pharmaceuticals reliant on multiple simultaneous binding events (polyvalence) interact with common biological structures, such as viruses and cells, in a manner that mimics natural processes. Tailored polyvalent dendrimers can interact simultaneously with these multiple binding targets, resulting in enhanced or novel pharmaceutical activity compared with conventional small molecule drugs.


A polyvalent interaction between a dendrimer
molecule and a biological surface. A typical interaction between a small
molecule and the same biological surface.

Designer ‘synthetic proteins’...
Dendrimers can be designed to be similar in size to biological structures, such as proteins. Dendrimers are suitable for the development of polyvalent pharmaceuticals with unique activities and applications, or for creating new and improved presentations of existing pharmaceuticals. Some features of dendrimers as drugs include:

Efficacy: active against a wide range of diseases;
Stability: stable as solids and in a variety of pharmaceutical formulations;
Toxicity: safe at therapeutic doses;
Identity / purity: reproducible and defined species;
Cost / ease of manufacture: cost effective, scaled-up cGMP manufacture.


Starpharma has developed a significant body of know-how associated with the repetitive synthesis and charecterisation of functionalised dendrimers as defined species.

Compared with large linear polymers, dendrimers are rigid structures that enable more predictable placement of surface groups and greater control of surface functionality. By altering the surface composition, dendrimers can be targeted to specific diseases, tissues or organs, and important properties such as bioavailability can be altered.

Starpharma has discovered and is developing dendrimers for a wide range of diseases. Starpharma has also identified a number of promising small molecular entities with activity against certain disease states.

[icepak]

@ PlanschProtectionTeam

Als ich auf GPC bei 7,50/70 vor kurzem hingewiesen habe, meinten auch einige:

" Die ist doch schon viel zu gut gelaufen "
" Die ist doch viel zu teuer"
"Was willste mit der Bude"?

Soviel dazu

[PlanschProtectionTeam]

@icepak

Hab mich mit dem Wert noch nicht beschäftigt und mag diese OTC-Dinger eigentlich nicht besonders.

Kannst Du bitte einen vernünftigen Chart einstellen?

Danke

[icepak]

Leider nicht, den das Teil wird erst seit kurzem bei uns gehandelt,der gibt noch nichts her !

Man sollte sich mal die Home-P. von Starpharma anschauen und durchlesen!

Ich finde es wirklich interessant !

Muss jeder selbst entscheiden!

Wollte nur mal darauf aufmerksam machen!

[icepak]

Das war vor einigen Tagen von mir in meinem GPC-Tr.zu lesen
was danach kam, weiss wohl jeder!




#9 von icepak 14.01.04 10:52:47 Beitrag Nr.: 11.838.722 11838722
Dieses Posting: versenden | melden | drucken | Antwort schreiben
etwas Geduld!

Die charttechn. Konst. wird auch bald pos.!
Momentum baut sich auf und irgendwann werden
wir weiter institut. Käufe sehen.

17 von icepak 14.01.04 11:22:02 Beitrag Nr.: 11.839.040 11839040
Dieses Posting: versenden | melden | drucken | Antwort schreiben
Momentan wird die Aktie noch im Bereich 8,40/50 " gedeckelt" .
aber das wird sich ändern!

Weitere News i.d.Pipeline!

Analysten-Meeting ist in Planung

[icepak]

Infos unter

www.Starpharma.com

[icepak]

Kurs zieht weiter an!

Gerade 0,68 in Frankfurt!

Sehe dieses Invest. als Langfristige Analge !

Dieses Segment in Verb. mit der AIDS-Forschung hat sehr viel Phantasie !

[icepak]

uups, geht weiter
0,70 zu 0,71

[icepak]

Die Umsätze in den letzten Min. in Frankfurt waren nicht schlecht !

T. & Sales mal anschauen

[icepak]

Noch nicht einmal am Tag des Herren ruhen die Börsen-Süchtigen

Man will sich ja informieren!

Zu Starpahrama.

Der "faire Kurs" liegt derzeit um 0,59
Deutschald-Aufschlag für den Michel vielleicht bei 0,60-0,62

Man sollte diese Aktien als spek. Long-Invest sehen!

Interessant ist das Teil auf jeden Fall !!

[icepak]

Neue Nano-Aktie Starpharma Pooled Development Ltd. (ISIN AU 000000SPLO/ WKN 796461)


nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat. Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, so genannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren und anderen bisher nur inadäquat behandelbaren Erkrankungen sein sollen. Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Spezialisierte chemische Prozesse erlauben es, die physikalischen und chemischen Eigenschaften der Dendrimere präzise zu kontrollierenDer Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind. Auf zwei Programme konzentriert sich Starpharma gegenwärtig, diese sollen bis in die Phase II, also bis zur Ermittlung einer Wirksamkeit im Menschen, geführt werden und im Anschluss daran an ein großes Pharmaunternehmen lizenziert werden. Das ‚Vaginal Microbicide Program—, zur Prävention von Erkrankungen die durch Geschlechtsverkehr übertragen werden, und das —Angiogenesis Inhibitor Program“, zur möglichen Therapie von Krebserkrankungen, befinden sich gegenwärtig noch in der präklinischen Entwicklung. Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll zuerst auf seine Wirksamkeit gegen HIV getestet werden. Allerdings konnten präklinische Studien auch eine Aktivität des Gels gegenüber Chlamydien und Genital-Herpes zeigen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein bisher kaum abschätzbares Marktvolumen erwarten.

[icepak]

In Ausr. wurde die 1$ Marke gebreakt!
All-time-High
Mit sehr hohem Volumen

[icepak]

Hoffen wir mal, dass es sich um eine Fake-Info bzgl. der Bäckermeister Frick handelt!

Den brauchen wir nicht "an board" von Starpharma !